A revolutionary new wearable sensor, which tracks tumors in real time, could provide invaluable insights into how cancer cells respond to treatments. The new device can report in real time how a tumor is growing or shrinking. The results are sent wirelessly to a smartphone for analysis, enabling physicians to more closely monitor patients' progress. So far, the device has been used and proven itself in animal studies. “Our technology is the first bioelectronic device to monitor tumor regression, and the first technology to monitor tumors in real time,” said Alex Abramson, PhD, assistant professor in the School of Chemical and Biomolecular Engineering at Georgia Tech and a co-author of a new study focusing the device. At present, the most common ways to measure tumors are calipers or bioluminescence imaging (BLI). While these methods are useful and, indeed, accurate, they are only typically performed every few days or weeks. With the new wearable sensor, tumor information is captured every 5 minutes, allowing changes to be recorded in a more timely fashion. Furthermore, the new sensor can also detect extremely small changes that calipers and BLI can’t. Our sensor will allow us to better understand the short-term effects of drugs on tumors and allow scientists and health care professionals a more streamlined method to screen drugs that could become therapies in the future,” Abramson added. *Image by Darko Stojanovic from Pixabay
A virus that infects and kills cancer cells has been injected into a human patient for the first time as part of a new clinical trial. The novel therapy, CF33-hNIS, also called Vaxinia, is what is known as a oncolytic virus i.e. one that deliberately targets cancel cells while avoiding healthy cells. It infiltrates the cancer cells and rapidly replicates, killing its host. At low doses, the therapy has been shown to reduce the size of a broad range of cancers in animal and laboratory models. And according to Imugene Limited, a clinical cancer research company, it can also help prime peoples' immune systems against cancer. For the phase one clinical trial, Vaxinia will be injected into people who have solid tumors and have received at least two types of prior treatment. The virus is either injected directly into the tumor itself or via the patient's vein. This phase of the trial is designed to judge Vaxinia's safety and tolerability in human patients. "Our previous research demonstrated that oncolytic viruses can stimulate the immune system to respond to and kill cancer, as well as stimulate the immune system to be more responsive to other immunotherapies," says City of Hope oncologist and principal investigator Daneng Li. "We believe CF33-hNIS has the potential to improve outcomes for our patients." *Image courtesy of PIRO4D from Pixabay
Liver cancer patients in France are benefiting from world-leading robot technology that is helping physicians treat and operate on them. The only two of their kind, the two robots, developed by Montpellier-based medical device company Quantum Surgical, assist oncologists in the delivery of a treatment known as “elimination by microwaves”. Prior to the addition of the robots, physicians needed to guide a tiny needle into a liver cancer patient’s tumor so that microwaves could be passed into it. Now, the robots carry out this part using 3D images with pinpoint accuracy. The robots are being used as part of a clinical trial at Montpellier Hospital that will test the technology on 20 patients. Currently, it is only being used on liver cancer patients, but the technology has been used target cancerous tumours in animals’ lungs and kidneys. Professor Thierry de Baère, head of therapeutic imaging at the Institut Gustave Roussy in Villejuif, one of Europe’s leading cancer centres and one of two in France where the robot is currently used, said: “The robot can put a small needle in exactly the right place, from the right direction and at the right depth.” Prof de Baère has performed five operations using the technology and all the patients were discharged the next day. *Image courtesy of Quantum Surgical
An innovative new blood test can detect breast cancer up to 5 years before symptoms appear, researchers say. Developed by a team at the University of Nottingham, England, the new blood test identifies specific immune system ‘autoantibodies’, which are produced when tumor-associated antigens (TAAs) are present – like those produced by breast cancer cells. While the test is still only partially effective, it could eventually provide the best chance of detecting breast cancer early, enabling faster treatment and a greater chance of success. In the pilot study, the researchers took blood samples from 90 breast cancer patients when they were diagnosed with breast cancer. They then matched these samples with ones from 90 patients without breast cancer. Then, they used a technology called protein microarray to test the blood samples for the presence of autoantibodies and 40 TAAs associated with breast cancer, plus another 27 TAAs that were not known to be linked with the disease). The researchers used a technology called protein microarray to rapidly test the blood samples for autoantibodies against 40 TAAs associated with breast cancer, plus another 27 TAAs that were not known to be linked with the disease. Speaking last Sunday at the U.K. National Cancer Research Institute conference in Glasgow, Scotland, researcher Daniyah Alfattani, a Ph.D. student at the University of Nottingham's Centre of Excellence for Autoimmunity in Cancer (CEAC), said: “The results of our study showed that breast cancer does induce autoantibodies against panels of specific tumor-associated antigens. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood.” At present, annual mammograms are the best way for doctors to detect the presence of breast cancer while in its early stages.
Male breast cancer is pretty rare. In fact, it accounts for just 1% of all breast cancer cases. That’s why very few studies have looked at what factors can lead to more positive outcomes for patients. To address this reality, researchers from Mayo Clinic in Rochester, Minnesota, have conducted one of the largest male breast cancer studies to date, the findings of which are published in the journal Cancer. The researchers found that 51% of male breast cancer diagnoses occurred between the ages of 50 and 69, and that the average age of diagnosis was 64. In fact, only 15% of the patients were diagnosed before the age of 50. Interestingly, the study authors found that black men, older patients, individuals with other ongoing health issue and those with higher tumor grade and stage had poorer prognoses. Furthermore, they found that patients who underwent a full mastectomy also had poorer outcomes. The prognosis was better for patients who lived in wealthier areas, whose tumors carried the progesterone receptor and men who received radiation therapy, chemotherapy or anti-estrogen therapy. While female breast cancer treatment has improved dramatically over the years, the study authors say it is unclear whether these advancements have been applied to the management of male breast cancer too. Two of the reasons for this are because male breast cancer usually occurs later in life and it commonly spreads to the person’s lymph nodes. The researchers hope their paper will shine some more light on this little known condition and lead to better outcomes for patients going forward.
A US study suggests that Artificial Intelligence (AI) is better than specialist doctors at identifying lung cancer. It’s a finding that could revolutionize cancer screening in the future, potentially allowing tumors to be found at an earlier stage and improving treatment outcomes. According to the study - which was conducted by researchers from Northwestern University in Illinois and the Google Health Research Group – Artificial Intelligence was able to outperform six specialist cancer doctors when it came to identifying cancer from a single CT scan. When multiple CT scans were used, the AI and the doctors were equally effective. Prior to the tests, the AI was trained with 42,290 CT lung scans from nearly 15,000 patients. It was not told what to look for in a CT scan, merely which patients went on to develop cancer and which didn’t. The results of the study, published in Nature Medicine, show that AI can not only boost cancer detection by 5%, but can also reduce false-positives by 11%. Speaking about the findings of the research, Dr Mozziyar Etemadi, from Northwestern University, said: “Not only can we better diagnose someone with cancer, we can also say if someone doesn't have cancer, potentially saving them from an invasive, costly, and risky lung biopsy.”
Les lauréats du Nobel de médecine 2018, James Allison et Tasuku Honjo, ont révolutionné l’approche pour traiter les tumeurs, en trouvant le moyen d’activer la réponse du système immunitaire. Le Prix Nobel de médecine 2018 récompense l’Américain James Allison et le Japonais Tasuku Honjo, deux chercheurs qui ont développé une approche totalement innovante contre les cancers. De manière isolée, les deux hommes ont trouvé le moyen d’activer le système immunitaire de l’organisme pour l’aider à éliminer lui-même des tumeurs, une technique en plein essor appelée immunothérapie. Cancer: l’immunothérapie cherche à repousser ses limites Jusque-là, les médecins avaient accès à trois voies majeures pour lutter contre les cancers: la chirurgie, la radiothérapie pour irradier les tumeurs et les médicaments s’attaquant aux cellules tumorales, comme la chimiothérapie. Les travaux de James Allison, du centre MD Anderson de l’université du Texas et Tasuku Honjo, de l’université de Kyoto, apportent ainsi une quatrième approche, en stimulant le système immunitaire. Lymphocytes T La clé de l’approche inventée par les deux scientifiques, de manière totalement indépendante l’un de l’autre, repose sur le fonctionnement les lymphocytes T, les cellules responsables de la réponse immunitaire de l’organisme. Dans le cas de la plupart des tumeurs, les lymphocytes T n’arrivent pas à percevoir les cellules cancéreuses comme une menace, et n’essaient même pas de les détruire. Immunothérapie et chimio, une combinaison gagnante contre certains cancers James Allison a découvert un récepteur sur les lymphocytes T, appelé CTLA4, qui agit comme un frein sur leur fonctionnement. Avec un anticorps spécifique ciblant ce récepteur, un anti-CTLA4, Allison a prouvé qu’il pouvait guérir des souris victimes de tumeurs. Un succès spectaculaire qui a par la suite été reproduit chez l’homme, d’abord pour des mélanomes, puis pour bien d’autres types de tumeurs par la suite. De son côté, Tasuku Honjo a découvert une protéine, PD1, qui pouvait elle aussi agir comme un frein pour empêcher les lymphocytes T d’agir. Indépendamment des travaux d’Allison, le chercheur japonais a lui aussi trouvé un moyen d’inhiber PD1, permettant aux cellules du système immunitaires de s’attaquer efficacement à des mélanomes, puis à de nombreuses autres tumeurs. Cyrille Vanlerberghe, Le Figaro France
Patients with aggressive brain tumours could benefit from improved surgery outcomes by drinking a substance that makes their cancer glow pink, a trial suggests. For the trial, scientists gave patients with suspected glioma (a type of tumor that occurs in the brain and spinal cord) a drink containing 5-ALA, a substance that accumulates in fast-growing cancer cells and makes them glow pink. The hope is that the glowing tumours will be easier for surgeons to safely remove, as they can be more easily distinguished from healthy brain tissue. Glioma is the most common type of brain cancer and treatment usually involves removing as much of the tumour as possible. The prognosis for patients, however, is usually poor. Speaking about the trial, Dr Kathreena Kurian, study author and associate professor in brain tumour research at the University of Bristol, said: “There's an urgent need to have something while the patient is on the table, while the neurosurgeon is operating, which will guide them to find the worst bits. “The beauty of 5-ALA is that they can see where high-grade glioma is, while they're operating.” The results of the trial have not yet been published, but were presented at the 2018 NCRI Cancer Conference in Glasgow over the weekend. The next step, the researchers say, is to test 5-ALA in children with brain tumours.
Clinique des Cèdres, Toulouse Clinique des Cèdres was created in 1966 thanks to Dr Anduze-Acher. Since then it became the biggest private hospital in France with 603 beds and places. In 2003, its acquisition by Capio group – already settled in Toulouse with Polyclinique du Parc, Clinique St Jean du Languedoc, Clinique de Beaupuy – helped its development. Clinique des Cèdres provides state-of-the Art equipment to its medical teams. Amongst the mini invasive surgical techniques: Robotic: In urology for the prostate cancer treatment, the kidney and bladder surgery In gynaecology for the uterus cancer surgery and the pelvic node dissection In ENT for the oral cavity, pharynx surgery, for the cellulo-node, nasopharyngeal surgery (cavum) Coelio-surgery for bariatric surgery Computer-aided surgery and strereotactic for the treatment of brain tumors Mini-invasive surgery for spine surgery (disc prothesis), orthopaedic surgery (perecutaneous foot surgery & trauma surgery) and rectal surgery (haemorrhoidal Doppler-assisted dearterization) 2. Advanced diagnosis techniques: Fluorescence technique in endoscopy for the early detection of lung cancers and bladder tumors 3D plan sensor in cardiology for the diagnosis and treatment of heart attacks and thoracic pains and in neuro radiology for the brain exploration and the therapeutic treatment of some brain vascular anomalies Non invasive Diagnosis-Imaging system: 64 strips scan Computerised diagnosis, evaluation, and follow-up care for knee cruciate ligament UNITS: 1. SURGICAL UNITS: more than 20 theatres covering a extremely wide variety of surgeries: Digestive surgery: ceolioscopy - endoscopy Orthopaedic surgery: arthroscopy Neurosurgery: neuronavigation device (O-arm concept) Ophthalmology ENT Outstanding surgical equipments include a stereotactic frame, a laminar flow, a laser, electronic microscopes and a DaVinci robot. 2. RECOVERY UNITS: the rooms are equipped with modern monitoring equipments and are under permanent anaesthetis supervision. Specialized nurses have the responsability of the post-operation personal follow-up care of the patient. 3. DIAGNOSIS AND MEDICAL IMAGING DEPARTMENT Angiography - Coronarography - Echigraphy - MRI - Mammography - Conventional and interventional radiology - Scan 4. NUCLEAR MEDICINE Functional and metabolic medical imagining, not accessible with conventional imaging equipment is performed in this department. 5. MEDICINE 6. INTENSIVE-CARE AND CONTINUOUS MONITORING UNIT 7. EMERGENCIES 8. HELIPAD 9. FUNCTIONAL PHYSIOTHERAPY 10. PSYCHIATRY 11. ONE-DAY HOSPITALISATION
Clinique de l'Alma, Paris The Clinique de l'Alma is a registered medical surgical health facility located at the foot of the Eiffel Tower in the heart of Paris. The Clinic has been developing its expertise and fields of activity since 1935 in order to offer to its patients high quality service using the most innovative and cutting edge techniques including some which have received world renown. Key figures In-patient hospital beds 83 The Clinique de l’Alma’s medical surgical specialties are: Digestive disease exploration and treatment field (oesophagus, stomach duodenum, small intestine and biliopancreatic system) Uro-nephrological field (haemodialysis and peritoneal dialysis renal failure treatment, renal calculi treatment, tumoral pathology treatment through regular surgery and coeliosurgery) General surgery field (gynaecological and mammary surgery, visceral and coelioscopic surgery, orthopaedic surgery, ophthalmological, ORL and stomatological surgery, plastic and cosmetic surgery) Vascular disease field The Clinique de l’Alma disposes of mini-invasive ambulatory hospitalisation techniques and soon non-invasive ambulatory hospitalisation surgery techniques in will be available. The clinic’s organisation is based on a multidisciplinary approach and it benefits of an international reputation.